FDA Issues Information Update on CBD

Share Post

The Food and Drug Administration (FDA) has issued a public document on cannabidiol (CBD) titled, “What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis derived Compounds, Including CBD,” which underscores the FDA’s concern with the safety of CBD. FDA does not believe it has enough information about certain aspects of CBD, such as what happens if someone takes CBD daily for sustained periods, and specifically identifies as a potential harm the use of CBD with alcohol because of the increased risk of sedation and drowsiness, which can lead to injuries. FDA also sent 15 warning letters to companies marketing CBD products that the agency views as unapproved drugs primarily because of the drug like claims made for such products. FDA continues to view putting into interstate commerce a food to which CBD has been added or to market CBD as or in a dietary supplement as a violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).